Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Grants to Canada and International Junior Investigators for Research Projects Related to ATTR Amyloidosis

Research Grant - Junior Investigator Global ATTR Amyloidosis Research ASPIRE

GrantWatch ID# 207903
Agency: Corporation

Funding Source
Pfizer Global Medical Grants (GMG)
Array ( )

Geographic Focus
International, Israel and Canada.

Important Dates
Deadline: 03/21/23 Save

Grant Description
Grants of up to $75,000 to Canada and International junior investigators for research projects related to ATTR amyloidosis. The purpose of the program is to support research to advance the treatment, diagnosis, and understanding of ATTR amyloidosis. Research projects must align with the funding source's research priorities.

This competitive grant program seeks to support research conducted by Junior Investigators that advances medical knowledge in the understanding, diagnosis and treatment of ATTR Amyloidosis.

Pfizer is interested in supporting research proposals that advance our understanding of the epidemiology, basic science and early diagnosis and treatment of ATTR amyloidosis through research focused in the following areas:

Epidemiologic evaluations for ATTR amyloidosis

  • Global or regionally-focused evaluations
  • Gender analysis – prevalence, natural history, etc.

Approaches for the early identification and follow up of ATTR amyloidosis patients

  • Multidisciplinary approaches to diagnosis and care
  • Multimodality imaging approaches to diagnosis including Artificial Intelligence (AI) and Machine Learning
  • New diagnostic algorithms
  • Non-invasive diagnostic techniques (e.g. biomarkers, use of AI)
  • Risk factors for disease penetrance
  • Definition and measurement disease progression and natural history studies
  • New staging systems
  • New outcomes measures (Quality of life; patient reported outcomes, Imaging)
  • Management of cardiac complications

RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR amyloidosis

  • Effect of Tafamidis on conduction disorders (i.e. arrhythmias, atrial fibrillation)
  • Effect of Tafamidis on ECHO, MRI or PET measures and hemodynamics
  • Effect of Tafamidis on amyloid burden
  • Effect of Tafamidis on quality of life
  • Changes in serum TTR, biomarker analysis
  • Evaluating existing databases for clinical outcomes
  • Use of tafamidis post-organ transplant

Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy)

  • RW treatment of mixed phenotype patients with Tafamidis 61mg including examination of both cardiac and neurological outcomes
  • Longitudinal evaluations of neurologic manifestations in patients with ATTR-CM including wild type
  • Case Control and Cross-Sectional Studies
  • Evaluating Existing Databases for clinical outcomes


  • Mechanistic studies to advance the basic science of amyloid formation and deposition including studies of the:
    • Functional role of TTR
    • Long term impact of TTR knockdown
  • Amyloidogenesis
    • Tissue tropism of amyloid deposits
    • Proteolytic cleavage


Additional Eligibility Criteria
Geographic Scope: All countries except for the United States

The applicant (PI) must be a junior investigator with a professional terminal degree (MD and/or PharmD or equivalent). Applicants must have obtained their terminal degree*less than 10 years ago.
*Terminal degree: end of training (i.e. residency/fellowship). The 10 years will begin after someone completes their training and begin a real teaching or patient care-focused job
• Applicant must be developing their research careers in ATTR Amyloidosis.
• Applicant must have a mentor or senior investigator participate as a co-investigator
• Members of the 2023 Expert Review Panel (ERP) and 2022 ASPIRE awardees are not eligible to apply or serve as mentors or collaborating investigators on applications from other investigators (this includes applications from junior investigators).
• The Junior Investigator must be listed as the PI in the application and the Mentor must be listed as the co-PI
• The principal investigator (PI) and institution must be based outside of the United States.
• Applicant must be affiliated with a host institution

Pre-Application Information
- RFP Release Date: 1/19/2023
- Proposal Due Date: 3/21/2023
- Anticipated Notification Date: July 2023

Estimated Size of Grant
Individual projects requesting up to $75,000 USD/year

Term of Contract
- Anticipated Project Timeline: up to 2 years
- Anticipated Project Start Date: December 2023

Contact Information
Apply online:

If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (, with the subject line “2023 RD G - Global ATTR Amyloidosis Research.”

Grant Writers For Hire - Grant Writer Team Grant News Grant Writers For Hire - Grant Writer Team
Live Chat Chat Now